Concord Pharmaceuticals is the first to submit a listing application for eliglustat capsule sumoscent

recently, Concord Pharmaceuticals has submitted the first domestic ipo application for Eliglustat capsules, the orphan drug's originaldrug(http://has not yet been listed in the country, Concord Pharmaceuticals is expected to take the first imitation of eliglustat capsulesOn August 19, 2014, SanofiCompany(http://'s Gosher disease treatment drug was approved by theFDA(http://, and the drug was approved by the EMA in January 2015Cerdelga's main ingredient is Eliglustat, which contains 84 mg of Eliglustat per capsuleEliglustat was originally developed by the University of Michigan, and Kenzan obtained the licenseIn November 2014, PDL acquired a portion of therights of the University of Michigan's Cerdelga GlobalPatent(http:// which resulted in a share of all royalties prior to the expiration of the grant 　　As a powerful, highly specific ceramide analogue inhibitor, Cerdelga reduces the production of glucose ceramide by targeting glucose ceramide synthetic (http:// enzymes for liver drug metabolism enzyme cell pigment P450 2D6 (CYP2D6) metabolic gene Long-term treatment of adult patients with type 1 gosser disease with weak metabolism, medium metabolism and fast metabolism is not suitable for a small number of patients who have been tested by genetic (http:// (CYP2D6) and are a first-line oral drug for the treatment of Godelga disease 　　Cerdelga's launch as the world's first oral gosser treatment drug has turned the previous market for injectable drug-led Goshey disease into a new treatment option for patients 　　This time, Concord Pharmaceuticals, the first in China to chemical drug 3 submitted the list of Eligrusta capsuleapplications, is currently in the "review and approval", is expected to take the first imitation of this orphan drug in the future, for the domestic community of Gosche disease patients to bring new treatment options